Clinical Trial Update: To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety, tolerability, and efficacy of LJN452 in patients with primary bile acid diarrhea has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Acid Diarrhea

Drugs mentioned

• LJN452

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Bile Acid Diarrhea | Phase 2 | Status: COMPLETED | Results posted: 2019-05-01